<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01975298</url>
  </required_header>
  <id_info>
    <org_study_id>LAQ-MS-306</org_study_id>
    <secondary_id>2013-002082-19</secondary_id>
    <nct_id>NCT01975298</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)</brief_title>
  <acronym>LIBRETTO</acronym>
  <official_title>A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate The Efficacy, Safety And Tolerability Of 2 Doses Of Oral Administration Of Laquinimod (0.6 mg/Day Or 1.2 mg/Day) Compared to Interferon ß-1a Administered Intra Muscular Once Weekly in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy, safety, and tolerability of two doses of&#xD;
      laquinimod compared to Avonex®&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Business Decision&#xD;
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain Atrophyas observed by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline and Month 12.</time_frame>
    <description>This is assessed by an MRI and is a measure of brain volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The cumulative number of reported influenza-like symptoms</measure>
    <time_frame>Baseline to Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative number of new T2 lesions observed by Magnetic Resonance Imaging (MRI) between the 2 laquinimod doses</measure>
    <time_frame>Baseline, Month 6 and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participant with Adverse Events</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Laquinimod 0.6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Laquinimod 1.2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Avonex®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Laquinimod</intervention_name>
    <description>Oral Administration</description>
    <arm_group_label>Laquinimod 0.6 mg</arm_group_label>
    <arm_group_label>Laquinimod 1.2 mg</arm_group_label>
    <other_name>TV-5600</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avonex®</intervention_name>
    <description>Interferon β1A 30 μg/0.5mL administered Intra Muscular</description>
    <arm_group_label>Avonex®</arm_group_label>
    <other_name>Interferon β1A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Subjects must have a confirmed and documented RRMS diagnosis as defined by the Revised&#xD;
             McDonald criteria, with relapse onset disease or a relapsing-remitting disease course.&#xD;
&#xD;
          -  Subjects must be ambulatory with an Kurtzke EDSS score of 0-5.5 at both Screening and&#xD;
             Baseline (randomization) visits.&#xD;
&#xD;
          -  Subjects must be in a stable neurological condition, relapse-free and free of any&#xD;
             corticosteroid treatment (intravenous [IV], IM and/or per os [PO]) or&#xD;
             adrenocorticotrophic hormone (ACTH), 60 days prior to randomization.&#xD;
&#xD;
          -  Subjects must have experienced at least 1 documented relapse in the last year prior to&#xD;
             randomization or 2 relapses in the last 3 years prior to randomization.&#xD;
&#xD;
          -  Subjects must be between 18 and 55 years of age at screening, inclusive.&#xD;
&#xD;
          -  Women of child-bearing potential must practice an acceptable method of birth control&#xD;
             until 30 days after the last dose of treatment was administered (acceptable methods of&#xD;
             birth control in this study include: surgical sterilization, intrauterine devices,&#xD;
             oral contraceptive, contraceptive patch, long-acting injectable contraceptive or&#xD;
             double-barrier method [condom or diaphragm with spermicide]).&#xD;
&#xD;
          -  Subjects must be able to sign and date a written informed consent prior to entering&#xD;
             the study.&#xD;
&#xD;
          -  Subjects must be willing and able to comply with the protocol requirements for the&#xD;
             duration of the study.&#xD;
&#xD;
               -  other criteria may apply, please contact the investigator for more information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with progressive forms of MS.&#xD;
&#xD;
          -  Subjects with Neuromyelitis Optica (NMO).&#xD;
&#xD;
          -  Use of experimental or investigational drugs and/or participation in drug clinical&#xD;
             studies within 6 months prior to Baseline visit (randomization).&#xD;
&#xD;
          -  Use of immunosuppressive agents, or cytotoxic agents, including cyclophosphamide and&#xD;
             azatioprine within 12 months prior to Baseline.&#xD;
&#xD;
          -  Natalizumab (Tysabri®) if given more than 6 months prior to randomization AND the&#xD;
             subject is John Cunningham (JC) virus antibody test negative at Screening.&#xD;
&#xD;
          -  Previous use of Rituximab, ocrelizumab, or ofatumumab is allowed if the B cell count&#xD;
             (CD19) is higher than 80 cells /μL.&#xD;
&#xD;
          -  Previous treatment with glatiramer acetate (Copaxone®e), fingolimod (Gilenya®), BG-12&#xD;
             (Tecfidera), Teriflunomide (Aubagio®) or intravenous immunoglobulin (IVIG) within 2&#xD;
             months prior to Baseline.&#xD;
&#xD;
          -  Use of mitoxantrone (Novantrone) within 5 years prior to Screening. Use of&#xD;
             mitoxantrone (Novantrone) &gt;5 years before screening is allowed in subjects with normal&#xD;
             ejection fraction and who did not exceed the total lifetime maximal dose.&#xD;
&#xD;
          -  Chronic (more than 30 consecutive days or monthly dosing, eg, with the intent of MS&#xD;
             disease modification) systemic (IV, IM or PO) corticosteroid treatment within 2 months&#xD;
             prior to Baseline.&#xD;
&#xD;
          -  Previous use of cladribine.&#xD;
&#xD;
          -  Previous use of laquinimod or Avonex® IM.&#xD;
&#xD;
          -  Treatment with other Interferon-β (either 1a subcutaneous [SC] or 1b SC) within 60&#xD;
             days before baseline (earlier treatment will be allowed if the reason for&#xD;
             discontinuation was not treatment failure or for Interferon-β related safety reasons.&#xD;
             This decision will be taken by the investigator).&#xD;
&#xD;
          -  Previous total body irradiation or total lymphoid irradiation.&#xD;
&#xD;
          -  Previous stem cell treatment, autologous bone marrow transplantation, or allogenic&#xD;
             bone marrow transplantation.&#xD;
&#xD;
          -  Acute infection within 2 weeks prior to Baseline visit.&#xD;
&#xD;
          -  Major trauma or surgery within 2 weeks prior to Baseline visit.&#xD;
&#xD;
          -  Use of moderate/strong inhibitors of CYP3A4 within 2 weeks prior to Baseline.&#xD;
&#xD;
          -  Use of inducers of CYP3A4 within 2 weeks prior to Baseline&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Serum levels ≥ 3 times (x) upper limit of normal (ULN) of either ALT or AST at&#xD;
             Screening.&#xD;
&#xD;
          -  Serum direct bilirubin ≥ 2xULN at Screening.&#xD;
&#xD;
          -  Subjects with a clinically significant or unstable medical or surgical condition or&#xD;
             any other condition that cannot be well-controlled by the allowed medications&#xD;
             permitted in the study protocol that would preclude safe and complete study&#xD;
             participation, as determined by medical history, physical examinations, ECG,&#xD;
             laboratory tests MRI or chest X-ray&#xD;
&#xD;
          -  Any acute pulmonary disorder.&#xD;
&#xD;
          -  A central nervous system disorder other than MS that may jeopardize the participation&#xD;
             in the study, including such disorders that are demonstrated on the baseline MRI.&#xD;
&#xD;
          -  A gastrointestinal disorder that may affect the absorption of study medication.&#xD;
&#xD;
          -  Renal disease.&#xD;
&#xD;
          -  Thyroid disease: hyperthyroidism, hypothyroidism.&#xD;
&#xD;
          -  Any form of acute or chronic liver disease.&#xD;
&#xD;
          -  Known human immunodeficiency virus positive status.&#xD;
&#xD;
          -  A clinical history of drug and/or alcohol abuse.&#xD;
&#xD;
          -  Unstable psychiatric disorder.&#xD;
&#xD;
          -  A history of seizure disorder, with the last convulsive episode within 12 months prior&#xD;
             to Screening visit.&#xD;
&#xD;
          -  Any malignancies, excluding basal cell carcinoma, in the 5 years prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Twenty or more gadolinium - enhancing lesions on baseline MRI.&#xD;
&#xD;
          -  A known history of sensitivity to gadolinium (Gd).&#xD;
&#xD;
          -  GFR ≤ 60 mL/min at the screening visit.&#xD;
&#xD;
          -  Inability to successfully/safely undergo MRI scanning.&#xD;
&#xD;
          -  Subjects who underwent endovascular treatment for Chronic Cerebrospinal Venous&#xD;
             Insufficiency (CCSVI).&#xD;
&#xD;
          -  Known hypersensitivity that would preclude administration of laquinimod capsule, such&#xD;
             as hypersensitivity to: mannitol, meglumine, or sodium stearyl fumarate.&#xD;
&#xD;
          -  A known history of hypersensitivity to natural or recombinant interferon β, human&#xD;
             albumin, or any other component of the formulation of Avonex®&#xD;
&#xD;
          -  Employees of the clinical study site or any other individuals involved with the&#xD;
             conduct of the study, or immediate family members of such individuals&#xD;
&#xD;
               -  other criteria may apply, please contact the investigator for more information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Branded Pharmaceutical Products R&amp;D, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 28, 2013</study_first_submitted>
  <study_first_submitted_qc>October 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2013</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RRMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

